Serologic Response to a New Recombinant, Adjuvanted Herpes Zoster Vaccine in Patients With Chronic Lymphocytic Leukemia and Waldenstr öm Macroglobulinemia Treated With First-Line BTK Inhibitors
Conditions: Chronic Lymphocytic Leukemia (CLL); Waldenstrom Macroglobulinemia (WM) Intervention: Drug: Shingrix vaccine Sponsor: University of Rochester Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials